Pear Bio

PreComb

This company develops a precision oncology platform using patient-derived microtumour models and automated analysis to predict drug responses for biopharmaceutical firms and clinical institutions.

Known Medicine

This company develops a platform using 3D cell culture and artificial intelligence to predict drug responses for oncologists and biopharmaceutical developers.

Xilis

Xilis develops miniature patient-derived tumour models for precision oncology and drug discovery, serving clinicians and pharmaceutical companies.

Solid IO

This company develops organ-on-chip technology to provide patient-specific insights for pharmaceutical companies and oncologists to improve cancer treatment decisions and drug development.

LiquidCell Dx

This company develops blood-based liquid biopsy tests for tumor microenvironment profiling to help pharmaceutical companies and clinical partners predict cancer therapy responses.

Organo-ID

The company develops 3D organoid models and drug response tests for cancer patients and pharmaceutical researchers to improve personalised medicine and treatment efficacy.

Kiyatec

This company develops 3D cell culture platforms to predict patient-specific responses to cancer therapies for oncologists and biopharmaceutical companies.

Lightcast Bio

This company develops a microfluidic platform for single-cell functional analysis for pharmaceutical companies and academic research institutions.